Isbn: 9781439862216 - thyroid cancer: from emergent biotechnologies to clinical practice guidelines (2 Ergebnisse)

ISBN
Mit der Detailsuche verfeinern

Optimieren Sie Ihre Suche

  • Bücher (2)

  • Neu (2)

bis

Benutzerdefinierte Preisspanne (EUR)

bis

    • Sprache: Englisch

      Verlag: CRC Press, 2011

      1439862214 / 9781439862216

      • Hardcover

      Anbieter: moluna, Greven, Deutschlandmoluna

      Verkäufer/-in mit 5 Sternen
      Verkäufer/-in kontaktieren

      Zustand: Neu

      EUR 180,58

      EUR 48,99 Versand 
      Versand von Deutschland nach USA

      Anzahl: Mehr als 20 verfügbar

      Gebunden. Zustand: New. Angelo Carpi, MD is a clinical researcher at the University Hospital of Pisa. He is also an associate professor of Internal Medicine at Pisa University. Jeffrey I. Mechanick, MD, Mount .

    • Sprache: Englisch

      Verlag: Taylor & Francis Inc Mai 2011, 2011

      1439862214 / 9781439862216

      • Hardcover

      Anbieter: AHA-BUCH GmbH, Einbeck, DeutschlandAHA-BUCH GmbH

      Verkäufer/-in mit 5 Sternen
      Verkäufer/-in kontaktieren

      Zustand: Neu

      EUR 230,23

      EUR 30,50 Versand 
      Versand von Deutschland nach USA

      Anzahl: 2 verfügbar

      Buch. Zustand: Neu. Neuware - 'Thyroid cancer evaluation and treatment has enjoyed very little evolution in comparison with other disease management strategies. The standard treatment algorithms for thyroid cancer have varied only in response to major, though infrequent, biotechnological innovations. These resultant algorithm node insertions produced paradigm changes, but there has been little to advance the care of the patient with advanced thyroid cancer--until very recently. Perhaps the reasons for a relative lack of interest and scientific progress are the overwhelming likelihood of benignity among thyroid nodules, the overwhelmingly favorable clinical outcome even if a patient has thyroid cancer, and the overwhelming long time required for clinical follow-up of these cancer patients. Unfortunately, the problem now is that we may be overmanaging low-risk patients, and we have not achieved the clinical responses we would have liked with high-risk patients'--Provided by publisher.